MyHep LVIR “Mylan recognizes the urgent need to expand access to high quality, affordable Hepatitis C treatment options in India, where roughly 12 million people are infected with the virus. It is an important addition to our growing Hepato Care segment in India that gives us the opportunity to offer patients the potential to be cured through a transformative and simplified single tablet, once-daily treatment regimen. Moreover, consistent with our commitment to create better health for a better world, we are introducing various educational initiatives in India to raise awareness of the disease and its treatment options.”
The launch of MyHep LVIR™ follows the successful launch of generic Sofosbuvir in India under the brand name MyHep™ in April 2015. In September 2014, Mylan entered into a licensing and technology transfer agreement with Gilead granting Mylan the non-exclusive rights to manufacture and distribute generic Sofosbuvir and Ledipasvir/Sofosbuvir tablets in 101 developing countries, including India.
Myhep LVIR Sofosbuvir 400mg + Ledipasvir 90mg is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug thatlegally requires a medical prescription to be dispensed.